R Street Institute Argues DEA's 7-OH Threshold Lacks Scientific Basis, Urges Product Regulation Over Scheduling

Why it matters

The R Street Institute's formal comment to HHS — submitted just before the August 5 deadline — provides the most detailed published critique of the DEA's proposed 0.050% / 1 mg per article threshold, arguing that no dose-response evidence exists to justify it and that scheduling may push users to more dangerous substances.

The big picture

R Street resident senior fellow Dr. Jeffrey S. Smith submitted a 7,000-word comment to HHS opposing the DEA's temporary Schedule I placement of 7-OH at the proposed concentration threshold. The comment argues that while the hazard of concentrated 7-OH is real, the specific numerical cutoff of 0.050% by weight or 1.00 mg per article has not been validated by any human dose-response study. Smith contends that DEA is converting a provisional product-identity screening tool into a criminal threshold without the evidence to support it — and that a regulated market with manufacturing standards, premarket review, and potency limits would be more effective and less harmful than emergency scheduling.

Key findings

• FDA's own 2025 scientific assessment acknowledges no controlled human clinical trial has established safe consumption limits for concentrated 7-OH, making any specific numerical Schedule I threshold scientifically unsupported.
• Preclinical studies show 7-OH causes respiratory depression and naloxone-reversible opioid effects in rats via IV administration — but these cannot be directly converted to human oral thresholds.
• The proposed 0.050% threshold equals 0.5 mg per gram; most of the problematic products identified in market studies contained 44 to 150 times that amount, making the cutoff both over- and under-inclusive.
• Schedule I status would not end research, but would add registration, security, and material-handling burdens that have historically delayed cannabis research by years.
• R Street recommends a tiered product framework: botanical leaf under labeling standards, concentrated products under potency/warning requirements, and synthetics requiring premarket authorization.

What they say

"Forgoing temporary scheduling is not a decision to ignore risk," wrote Dr. Smith. "It is a decision to regulate the measured risks directly, to avoid overstating what the science can presently prove, and to build the evidence needed for durable public health policy."

Bottom line

The most detailed independent policy analysis of the DEA's 7-OH scheduling order concludes that the proposed 1 mg threshold is scientifically indefensible on current evidence and that targeted product regulation would better protect public health.